As NCATS scientific director, Hall will lead the Division of Preclinical Innovation (DPI). DPI conducts collaborative preclinical research projects for common and rare diseases, and it develops new methods and technologies that speed translational research. Hall succeeds Anton Simeonov, who guided DPI to an array of translational science achievements and partnerships.
Hall, who began his new role in January, is committed to strengthening the center’s role as a world-class translational science hub.
“I am excited to continue our culture of teamwork to bring new therapies to people, particularly in underserved areas like rare diseases,” Hall said. “I also look forward to building partnerships with other NIH institutes and centers, including NIH extramural partnerships. The NIH environment is one that lets us innovate scientifically, but also organizationally. There’s incredible opportunity to create integrated research environments from multiple ICs on the intramural side. I’d like to find the best way to tackle scientific challenges, and a big part of that is building working relationships across NIH. I think conversations can lead to innovation for patients.”
